Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

333

Participants

Timeline

Start Date

November 7, 2016

Primary Completion Date

April 2, 2024

Study Completion Date

April 2, 2024

Conditions
Malignancies
Interventions
DRUG

REGN3767

DRUG

cemiplimab

Trial Locations (43)

3000

Peter Maccallum Cancer Centre (PMCC), Melbourne

4029

Royal Brisbane and Women's Hospital, Brisbane

10016

Laura & Isaac Perlmutter Cancer Center, New York

10032

Columbia University, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

11042

Northwell Health-Monter Cancer Center, Lake Success

14263

Roswell Park Cancer Institute, Buffalo

20007

Lombardi Comprehensive Cancer Center - MedStar Georgetown University Hospital, Washington D.C.

22031

Virginia Cancer Care Specialist, PC, Fairfax

28204

Levine Cancer Institute, Charlotte

29425

Hollings Cancer Center - Medical University of South Carolina, Charleston

30322

Winship Cancer Institute at Emory University, Atlanta

32806

Orlando Health, Inc, Orlando

33176

Miami Cancer Institute, Miami

37203

Sarah Cannon Research Institute, Nashville

44087

University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland

48202

Henry Ford Health Hospital, Detroit

49503

Cancer and Hematology Centers of Western Michigan, Grand Rapids

63110

Washington University in Saint Louis, St Louis

66205

University of Kansas Clinical Research Center, Fairway

73104

Stephenson Cancer Center, Oklahoma City

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

South Texas Oncology and Hematology, San Antonio

80045

University of Colorado Cancer Center, Aurora

87131

New Mexico Cancer Care Alliance-UNM Cancer Center, Albuquerque

90025

The Angeles Clinic, Los Angeles

92024

California Cancer Associates for Research and Excellence, Encinitas

93720

California Cancer Associates For Research And Excellence, Fresno

94115

California Pacific Medical Center (CPMC), San Francisco

95817

University of California Davis Health Systems, Sacramento

92093-0698

University of California San Diego (UCSD), La Jolla

02130

Dana Farber Cancer Institute, Jamaica Plain

07601

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

02903

Rhode Island Hospital, Providence

06009

The University of Western Australia - The Queen Elizabeth II Medical Centre (QEIIMC) - Sir Charles Gairdner Hospital (SCGH), Perth

D04 T6F4

St. Vincents University Hospital, Dublin

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

SE19RT

Guy's Hospital, London

OX37LJ

University Of Oxford - Churchill Hospital, Headington

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03005782 - Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers | Biotech Hunter | Biotech Hunter